CLASS ACTION UPDATE for UL, TGTX and ENOB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / August 10, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

UL Shareholders Click Here: https://www.zlk.com/pslra-1/unilever-plc-loss-submission-form?prid=30748&wire=1
TGTX Shareholders Click Here: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30748&wire=1
ENOB Shareholders Click Here: https://www.zlk.com/pslra-1/enochian-biosciences-loss-submission-form?prid=30748&wire=1

* ADDITIONAL INFORMATION BELOW *

Unilever PLC UL

This lawsuit is on behalf of all persons who purchased or otherwise acquired Unilever American Depositary Receipts between September 2, 2020 and July 21, 2021, inclusive.
Lead Plaintiff Deadline : August 15, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/unilever-plc-loss-submission-form?prid=30748&wire=1

According to the filed complaint, a) in July 2020, the board of Ben & Jerry's, one of Unilever's marquee brands, passed a resolution to end sales of its ice cream in "Occupied Palestinian Territory" ; and b) this boycott decision risked adverse governmental actions for violations of laws, executive orders, or resolutions aimed at discouraging boycotts, divestment, and sanctions of Israel adopted by 35 U.S. states.

TG Therapeutics, Inc. TGTX

TGTX Lawsuit on behalf of: investors who purchased January 15, 2020 - May 31, 2022
Lead Plaintiff Deadline : September 16, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/tg-therapeutics-loss-submission-form?prid=30748&wire=1

According to the filed complaint, during the class period, TG Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) clinical trials revealed significant concerns related to the benefit-risk ratio and overall survival data of the Company's therapeutic product candidates, Ublituximab and Umbralisib; (ii) accordingly, it was unlikely that the Company would be able to obtain approval from the U.S. Food and Drug Administration of the Umbralisib marginal zone lymphoma and follicular lymphoma New Drug Application, the Biologics License Application for Ublituximab in combination with Umbralisib, the supplemental New Drug Application for Ublituximab in combination with Umbralisib, or the Ublituximab relapsing forms of multiple sclerosis Biologics License Application in their current forms; (iii) as a result, the Company had significantly overstated Ublituximab and Umbralisib's clinical and/or commercial prospects; and (iv) therefore, the Company's public statements were materially false and misleading at all relevant times.

Enochian BioSciences, Inc. ENOB

ENOB Lawsuit on behalf of: investors who purchased January 17, 2018 - June 27, 2022
Lead Plaintiff Deadline : September 26, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/enochian-biosciences-loss-submission-form?prid=30748&wire=1

According to the filed complaint, during the class period, Enochian BioSciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's co-founder and inventor Serhat Gumrukcu was engaged in a variety of frauds; (2) Gumrukcu was not a licensed doctor anywhere in the world; (4) as a result of the foregoing, Gumrukcu's purported contributions to the Company lacked a reasonable basis; (5) as a result of the foregoing, the Company had overstated its commercial prospects; (6) Gumrukcu had improperly diverted approximately $20 million from Enochian to entities he owned; and (7) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP